IONTAS and FairJourney Biologics (FJB) have entered into an agreement with Quell Therapeutics regarding IONTAS / FJB’s proprietary libraries and technology platforms.
A diverse panel of novel target binders from IONTAS and FairJourney Biologics (FJB) will be used to identify antibodies to advance Quell’s engineered Treg cell therapy pipeline.
Quell harnesses the suppressive capacity of Tregs to develop engineered Treg cell therapies that address several conditions of immune dysfunction. Under the terms of the agreements, IONTAS and FairJourney Biologics will provide Quell with a panel of target binders, ranging in affinities, to enable Quell to select functional binders for chimeric antigen receptor (CAR) development against undisclosed targets.
Dr Antonio Parada, CEO at IONTAS, said: “Our experience in antibody discovery for use in cell-based therapies has grown in recent years, with a number of undisclosed partnerships rapidly moving towards the clinic. This insight will allow us to address the specific needs of Quell and we look forward to generating a diverse set of antibodies for further study and eventual clinical use by Quell in their engineered Treg cell therapy product candidates.”
Dr Luke Henry, Vice President Operations & Corporate Development at Quell Therapeutics, said: “The experience in antibody discovery shared by IONTAS and FJB, together with their unique library of target binders, makes them ideal partners as we focus on expanding our pipeline into autoimmune diseases and neuroinflammation.”
Image credit: Cytonn Photography
